News

Aralez has signed an agreement to sell its VIMOVO royalties and Canadian operations to Nuvo Pharmaceuticals for $110m. In another deal, the company agreed to offload its TOPROL-XL

Onpattro is claimed to be the first-of-its-kind RNAi therapeutic and only FDA-approved treatment for this indication. Earlier, Onpattro secured breakthrough therapy and orphan drug designations from the FDA.

The financing was led by Novo Holdings and joined by new investors Cowen Healthcare Investments, Pfizer Ventures and funds managed by Tekla Capital Management. Existing investors Versant Ventures,

Millendo is engaged in the development of novel treatments for orphan endocrine diseases. The combined company will further advance Millendo’s pipeline of transformative treatments for orphan endocrine diseases.

The expanded agreement will explore the potential of the Moditope® platform to develop multiple immunotherapeutic agents for a range of different cancers. Scancell’s Moditope® platform technology uses citrullinated

Continuing its focus on enhancing shareholder value, the Board believes a separation of the Rx business will better enable this unique asset to capitalize on its platform of

The partnership announcement coincided with official launch of Ambys Medicines with a $60m Series A financing funded by Third Rock Ventures and Takeda. The partnership with Takeda brings

The $15m Series B financing was led by Decheng Capital and the recent $58m Series C financing was led by 3E Bioventures Capital, Virtus Inspire Ventures, and SV

The product is a novel therapeutic antibody, Clevegen, being developed by clinical stage biotechnology company, Faron Pharmaceuticals. The manufacture of this product took place at Abzena’s site in